SWOT Analysis for SMS Pharmaceuticals Ltd.

Add SWOT widget to your site/app

Relative Outperformance versus Industry over 1 Year
High DVM Mid and Small Caps (subscription)
Growth Factor Screener: Rising returns on equity (ROE), Momentum, and Earnings Yield
Benjamin Graham Value Screen
Price crossing above SMA20 today, and greater than SMA5
Strong Performer, Getting Expensive (DVM)
30 Day SMA crossing over 200 Day SMA, and current price greater than open
Companies with 10% increase in share price over three months, with rising net profit growth
Stock passes majority of CANSLIM Investment criteria
Strong Momentum: Price above short, medium and long term moving averages
Consistent high performing stocks over Five Years
Relative Outperformance versus Industry over 1 Month
Companies with high TTM EPS Growth
Annual Profit Growth higher than Sector Profit Growth
PEG lower than Industry PEG
High Momentum Scores (Technical Scores greater than 50)
Relative Outperformance versus Industry over 1 Week
Relative Outperformance versus Industry over 1 Month
Effectively using its capital to generate profit - RoCE improving in last 2 years
Effectively using Shareholders fund - Return on equity (ROE) improving since last 2 year
Efficient in managing Assets to generate Profits - ROA improving since last 2 year
Growth in Quarterly Net Profit with increasing Profit Margin (YoY)
Companies with Low Debt
Increasing profits every quarter for the past 4 quarters
Strong cash generating ability from core business - Improving Cash Flow from operation for last 2 years
Annual Net Profits improving for last 2 years
Book Value per share Improving for last 2 years
Near 52 Week High
RSI indicating price strength
High Volume, High Gain
Top Gainers
High Volume, High Gain
Volume Shockers
Stocks near 52 Week High with Significant Volumes
Stocks Outperforming their Industry Price Change in the Quarter

Relative Outperformance versus Industry over 1 Year

High DVM Mid and Small Caps (subscription)

Growth Factor Screener: Rising returns on equity (ROE), Momentum, and Earnings Yield

Benjamin Graham Value Screen

Price crossing above SMA20 today, and greater than SMA5

Strong Performer, Getting Expensive (DVM)

30 Day SMA crossing over 200 Day SMA, and current price greater than open

Companies with 10% increase in share price over three months, with rising net profit growth

Stock passes majority of CANSLIM Investment criteria

Strong Momentum: Price above short, medium and long term moving averages

Consistent high performing stocks over Five Years

Relative Outperformance versus Industry over 1 Month

Companies with high TTM EPS Growth

Annual Profit Growth higher than Sector Profit Growth

PEG lower than Industry PEG

High Momentum Scores (Technical Scores greater than 50)

Relative Outperformance versus Industry over 1 Week

Relative Outperformance versus Industry over 1 Month

Effectively using its capital to generate profit - RoCE improving in last 2 years

Effectively using Shareholders fund - Return on equity (ROE) improving since last 2 year

Efficient in managing Assets to generate Profits - ROA improving since last 2 year

Growth in Quarterly Net Profit with increasing Profit Margin (YoY)

Companies with Low Debt

Increasing profits every quarter for the past 4 quarters

Strong cash generating ability from core business - Improving Cash Flow from operation for last 2 years

Annual Net Profits improving for last 2 years

Book Value per share Improving for last 2 years

Near 52 Week High

RSI indicating price strength

High Volume, High Gain

Top Gainers

High Volume, High Gain

Volume Shockers

Stocks near 52 Week High with Significant Volumes

Stocks Outperforming their Industry Price Change in the Quarter

Promoters increased pledged shares QoQ
Declining Net Cash Flow : Companies not able to generate net cash
Increasing Trend in Non-Core Income
High promoter stock pledges
Highest increase in pledges by promoters
Sell Zone: Stocks in the sell zone based on days traded at current PE and P/BV

Promoters increased pledged shares QoQ

Declining Net Cash Flow : Companies not able to generate net cash

Increasing Trend in Non-Core Income

High promoter stock pledges

Highest increase in pledges by promoters

Sell Zone: Stocks in the sell zone based on days traded at current PE and P/BV

Mutual Funds Increased Shareholding in Past Month
Big Deal (Insider and SAST) buys last month greater than 1% of total shares
Big Deal (Insider and SAST) buys last week greater than 1% of total shares
FII / FPI or Institutions increasing their shareholding
Mutual Funds Increased Shareholding over the Past Two Months
Mf buying for 2 months

Mutual Funds Increased Shareholding in Past Month

Big Deal (Insider and SAST) buys last month greater than 1% of total shares

Big Deal (Insider and SAST) buys last week greater than 1% of total shares

FII / FPI or Institutions increasing their shareholding

Mutual Funds Increased Shareholding over the Past Two Months

Mf buying for 2 months

MFs decreased their shareholding last quarter
US FDA Warning Letter

MFs decreased their shareholding last quarter

US FDA Warning Letter

Promoters increasing shareholding QoQ
Rising Delivery Percentage Compared to Prev Day
Rising Delivery Percentage Compared to Previous Day and Month, Strong Volumes
Average Bullish Trend - Stocks with Medium Trendlyne Momentum Score versus Benchmarks

Promoters increasing shareholding QoQ

Rising Delivery Percentage Compared to Prev Day

Rising Delivery Percentage Compared to Previous Day and Month, Strong Volumes

Average Bullish Trend - Stocks with Medium Trendlyne Momentum Score versus Benchmarks

SMS Pharmaceuticals Ltd. SWOT Analysis: Strengths, Weakness, Opportunity, and Threats

SMS Pharmaceuticals Ltd. has 35 Strengths, 6 Weaknesses, 6 Opportunities and 2 Threats. The SWOT product gives you a quick x-ray of a stock's outlook and potential